Xiamen Amoytop Biotech Co Ltd
SSE:688278
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
44.42
83.41
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Xiamen Amoytop Biotech Co Ltd
Total Liabilities
Xiamen Amoytop Biotech Co Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
X
|
Xiamen Amoytop Biotech Co Ltd
SSE:688278
|
Total Liabilities
¥479.7m
|
CAGR 3-Years
36%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Liabilities
¥16B
|
CAGR 3-Years
13%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Liabilities
¥2.9B
|
CAGR 3-Years
62%
|
CAGR 5-Years
69%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Liabilities
¥3B
|
CAGR 3-Years
47%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Liabilities
¥1.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
35%
|
CAGR 10-Years
12%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Liabilities
¥23.3B
|
CAGR 3-Years
27%
|
CAGR 5-Years
32%
|
CAGR 10-Years
64%
|
|
Xiamen Amoytop Biotech Co Ltd
Glance View
Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Xiamen Amoytop Biotech Co Ltd's Total Liabilities?
Total Liabilities
479.7m
CNY
Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's Total Liabilities amounts to 479.7m CNY.
What is Xiamen Amoytop Biotech Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
18%
Over the last year, the Total Liabilities growth was 32%. The average annual Total Liabilities growth rates for Xiamen Amoytop Biotech Co Ltd have been 36% over the past three years , 18% over the past five years .
You don't have any saved screeners yet
